title: (3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies.
abstract: Quantitative characterization of the in vivo effects of vascular-targeted therapies on tumor vessels is hampered by the absence of useful 3D vascular network descriptors aside from microvessel density. In this study, we extended the quantification of planar vessel distribution to the analysis of vascular volumes by studying the effects of antiangiogenic (sorafenib and sunitinib) or antivascular (combretastatin A4 phosphate) treatments on the quantity and spatial distributions of thin microvessels. These observations were restricted to perinecrotic areas of treated human multiple myeloma tumors xenografted in immunodeficient mice and to microvessels with an approximate cross-sectional area lower than 75 µm(2). Finally, vessel skeletonization minimized artifacts due to possible differential wall staining and allowed a comparison of the various treatment effects. Antiangiogenic drug treatment reduced the number of vessels of every caliber (at least 2-fold fewer vessels vs. controls; p<0.001, n = 8) and caused a heterogeneous distribution of the remaining vessels. In contrast, the effects of combretastatin A4 phosphate mainly appeared to be restricted to a homogeneous reduction in the number of thin microvessels (not more than 2-fold less vs. controls; p<0.001, n = 8) with marginal effects on spatial distribution. Unexpectedly, these results also highlighted a strict relationship between microvessel quantity, distribution and cross-sectional area. Treatment-specific changes in the curves describing this relationship were consistent with the effects ascribed to the different drugs. This finding suggests that our results can highlight differences among vascular-targeted therapies, providing hints on the processes underlying sample vascularization together with the detailed characterization of a pathological vascular tree.
authors.affiliation: Institute of Neuroscience, Consiglio Nazionale delle Ricerche, Milan, Italy. m.righi@in.cnr.it
authors.forename: Marco
authors.initials: M
authors.lastname: Righi
authors.forename: Arianna
authors.initials: A
authors.lastname: Giacomini
authors.forename: Loredana
authors.initials: L
authors.lastname: Cleris
authors.forename: Carmelo
authors.initials: C
authors.lastname: Carlo-Stella
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016477:Artifacts; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic; D005260:Female; D006801:Humans; D021621:Imaging, Three-Dimensional / Q000379:methods*; D008223:Lymphoma / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D055806:Microvessels / Q000187:drug effects / Q000378:metabolism; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013267:Stilbenes; C058728:fosbretabulin
references.citation: Mol Cancer Ther. 2008 Oct;7(10):3129-40
references.pmid: 18852116
references.citation: Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14765-70
references.pmid: 8962129
references.citation: J Med Chem. 2003 Mar 27;46(7):1116-9
references.pmid: 12646019
references.citation: Cancer. 2010 Apr 15;116(8):1859-71
references.pmid: 20166210
references.citation: Cancer Res. 2006 Dec 15;66(24):11851-8
references.pmid: 17178882
references.citation: Microvasc Res. 2012 Nov;84(3):314-22
references.pmid: 22796313
references.citation: Blood. 2003 May 1;101(9):3597-605
references.pmid: 12531805
references.citation: Histol Histopathol. 2008 May;23(5):601-7
references.pmid: 18283645
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: Clin Cancer Res. 2003 Jan;9(1):327-37
references.pmid: 12538485
references.citation: Blood. 2010 Mar 18;115(11):2231-40
references.pmid: 20075160
references.citation: Med Phys. 1987 Jul-Aug;14(4):533-7
references.pmid: 3626992
references.citation: Cancer Res. 1997 May 15;57(10):1829-34
references.pmid: 9157969
references.citation: Comput Methods Programs Biomed. 2012 Aug;107(2):140-54
references.pmid: 21803438
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3942-50
references.pmid: 17606728
references.citation: N Engl J Med. 1991 Jan 3;324(1):1-8
references.pmid: 1701519
references.citation: Cancer Cell. 2009 Mar 3;15(3):232-9
references.pmid: 19249681
references.citation: Mol Cancer Ther. 2003 May;2(5):471-8
references.pmid: 12748309
references.citation: Lab Invest. 2009 Sep;89(9):1063-70
references.pmid: 19652644
references.citation: J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
references.pmid: 1688381
references.citation: Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):416-20
references.pmid: 15701823
references.citation: Med Image Anal. 2001 Jun;5(2):111-26
references.pmid: 11516706
references.citation: Science. 2005 Jan 7;307(5706):58-62
references.pmid: 15637262
references.citation: Cancer Res. 2010 Feb 1;70(3):1053-62
references.pmid: 20103629
references.citation: Nature. 2011 May 19;473(7347):298-307
references.pmid: 21593862
references.citation: Cancer Cell. 2009 Mar 3;15(3):220-31
references.pmid: 19249680
references.citation: Cancer Res. 2004 Jun 1;64(11):3731-6
references.pmid: 15172975
references.citation: In Vitro Cell Dev Biol. 1989 Aug;25(8):723-9
references.pmid: 2768132
references.citation: Cancer Lett. 2011 Mar 1;302(1):11-9
references.pmid: 21236562
references.citation: PLoS One. 2011;6(6):e20807
references.pmid: 21694777
references.citation: Int J Cancer. 2002 Nov 1;102(1):70-4
references.pmid: 12353236
references.citation: J Clin Oncol. 2007 Mar 1;25(7):884-96
references.pmid: 17327610
references.citation: Comput Biol Med. 2005 Nov;35(9):791-813
references.pmid: 16278109
references.citation: J Microsc. 2011 Jun;242(3):262-78
references.pmid: 21118252
references.citation: Int J Oncol. 2002 Oct;21(4):717-26
references.pmid: 12239609
references.citation: Cancer Res. 2001 Sep 1;61(17):6413-22
references.pmid: 11522635
references.citation: PLoS One. 2011;6(11):e27385
references.pmid: 22110636
references.citation: Nat Methods. 2005 Apr;2(4):291-8
references.pmid: 15782212
references.citation: J Clin Invest. 2006 Mar;116(3):642-51
references.pmid: 16470244
references.citation: Methods Enzymol. 2006;407:597-612
references.pmid: 16757355
references.citation: J Microsc. 2004 Aug;215(Pt 2):139-48
references.pmid: 15315500